ReviewPharmacogenomics2018
Pharmacogenetics of warfarin dosing in patients of African and European ancestry.
Review in Pharmacogenomics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Warfarin dosing algorithms: A systematic review.British journal of clinical pharmacology · 2021Pooled it
- Comparison of Warfarin Initiation at 3 mg Versus 5 mg for Anticoagulation of Patients with Mechanical Mitral Valve Replacement Surgery: A Prospective Randomized Trial.Clinical drug investigation · 2022Trial
- Bridging Ancestry-Stratified Bias in Pharmacogenomics AI: Toward Metabolomics-Inclusive Multi-Omics Precision Medicine.Journal of personalized medicine · 2026Review
- Conceptual frameworks for the integration of genetic and social epidemiology in complex diseases.Global epidemiology · 2024Article
- Mining local exome and HLA data to characterize pharmacogenetic variants in Saudi Arabia.Human genetics · 2024Article
- Pharmacogenetics of warfarin dosing in Chinese adults with nonvalvular atrial fibrillation.European journal of clinical pharmacology · 2023Article
- Pharmacogenomics and health disparities, are we helping?Frontiers in genetics · 2023Review
- On the Verge of Precision Medicine in Diabetes.Drugs · 2022Review
- The Impact of CYP2C9*11 Allelic Variant on the Pharmacokinetics of Phenytoin and (S)-Warfarin.Clinical pharmacology and therapeutics · 2022Article
- Ethnic Diversity and Warfarin Pharmacogenomics.Frontiers in pharmacology · 2022Review
- Evaluation of population-level pharmacogenetic actionability in Alabama.Clinical and translational science · 2021Article
- Prevalence of five pharmacologically most importantArhiv za higijenu rada i toksikologiju · 2021Article
- Pharmacogenomics for Primary Care: An Overview.Genes · 2020Review
- Enrollment of Diverse Populations in the INGENIOUS Pharmacogenetics Clinical Trial.Frontiers in genetics · 2020Article
- Issues in the Use of Human Tissues to Support Precision Medicine.Journal of health care for the poor and underserved · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Despite the introduction of direct acting oral anticoagulants, warfarin remains the most commonly prescribed oral anticoagulant. However, warfarin therapy is plagued by the large inter- and intrapatient variability. The variability in dosing fueled research to identify clinical and genetic predictors and develop more accurate dosing algorithms. Observational studies have demonstrated the significant impact of single nucleotide polymorphisms in CYP2C9 and VKORC1 on warfarin dose in patients of European ancestry and African-Americans. This evidence supported the design and conduct of clinical trials to assess whether genotype-guided dosing results in improved anticoagulation control and outcomes. The trial results have shown discordance by race, with pharmacogenetic algorithms improving dose and anticoagulation control among European ancestry patients compared with African-American patients. Herein, we review the evidence from observational and interventional studies, highlight the need for inclusion of minority race groups and propose the need to develop race specific dosing algorithms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.